Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa

摘要：项目2：HIV相关卡波西肉瘤的临床和分子决定因素 马拉维和南非当地护理标准治疗的进展 本申请旨在建立北卡罗来纳-马拉维-南非癌症联盟(UMSACC)。它会回应 符合RFA-CA-20-001，并将建立一个研究中心，以发展能力并进行高影响力的研究 专注于 美国和中低收入国家的艾滋病毒相关恶性肿瘤。项目2--卡波西 肉瘤建立在北卡罗来纳大学教堂山分校 灯塔信托基金/马拉维的卡穆祖中心医院和斯泰伦博什大学/泰格伯格医院 南非。该项目有来自美国、马拉维和韩国这三个国家的调查人员参与 非洲。UMSACC将建立和维护核心，支持指导、管理、病理和 对三个项目进行联合分析。卡波西肉瘤是迄今为止居住在印度的最常见的癌症。 撒哈拉以南非洲的艾滋病毒携带者和美国的护理标准，脂质体阿霉素，负担不起或 在公共部门提供。建立在艾滋病恶性肿瘤联盟最近的随机临床试验基础上 和艾滋病临床试验小组，我们将记录紫杉醇/CART作为新的一线的经验 治疗HIV-KS并寻求开发这种疾病的预后生物标志物，如KSHV病毒载量、IL6、 KSHV的序列变异和转录。

ABSTRACT: PROJECT 2. Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa This application seeks to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC). It responds to RFA-CA-20-001 and will establish a research center to develop capacity and conduct high-impact research focused on HIV-Associated Malignancy in U.S. and Low- and Middle-Income Country. Project 2 - Kaposi Sarcoma builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust / Kamuzu Central Hospital in Malawi, and Stellenbosch University / Tygerberg Hospital in South Africa. This project has participation of investigators from all three countries: the US, Malawi and South Africa. UMSACC will establish and maintain core that support mentoring, administration, pathology and analyses jointly across three projects. Kaposi sarcoma is by far the most common cancer in people living in with HIV in Sub Saharan Africa and the US standard of care, liposomal doxorubicin, is not affordable or available in the public sector. Building on recent randomized clinical trials by the AIDS malignancy Consortium and the AIDS clinical trials group, we will document the experience with paclitaxel/ cART as new first line therapy in HIV-KS and seek to develop prognostic biomarkers of the disease, such as KSHV viral load, IL6, KSHV sequence variants and KSHV transcription.